New insights into diabetic blindness

Apr 09, 2010
New insights into diabetic blindness
Retinal vasculature of an adult transgenic (Fli1:EGFP) zebrafish. After 30 days of hyperglycaemia, these vessels display many of the abnormal features observed in the retinal capillaries of diabetic patients.

(PhysOrg.com) -- New research by University College Dublin scientists indicates that treatment of diabetic blindness should look at protecting the neurons responsible for colour vision in the eye and not just targeting the blood vessels as is currently the practice.

The research team led by Conway Fellow, Dr Breandán Kennedy from the School of Biomolecular & Biomedical Science recently published their findings in the journal Disease Models & Mechanisms.

Nearly 2.5 million people worldwide are blind due to a secondary complication of diabetes called diabetic retinopathy. This disorder activates the growth of new leaky in the eye and is responsible for the death of photoreceptors, the neurons that send visual messages to our brain.

Until now, scientists were unclear if the changes to vessels and neurons occurred independently of one other. Questions were also asked about which type of retinal neuron is most likely to die as a result of the raised glucose levels seen in diabetes.

Dr Kennedy and his team found that new blood vessels and the neuronal cell death in diabetic retinopathy can arise independently of each other. In addition, they identified that cone photoreceptor neurons, those involved in and which we use to see during daylight are most affected by the high glucose levels.

The research team made their observations by successfully generating a zebrafish model of diabetes. The eyes of these small, tropical freshwater fish are very similar in design to humans, making it a useful species to study blindness. The high levels of glucose typically seen in people suffering with diabetes were stimulated in zebrafish and the fish studied to see whether they exhibited known diabetic symptoms.

This novel model of the disease resembles the early stages of diabetic retinopathy in humans. It is an exciting development for the Kennedy group who now hope to further extend their research and establish a model of late stage diabetic disease.

Current treatment for diabetic retinopathy sufferers tries to prevent the growth of new blood vessels in the late stage of the disease. There are associated side effects and the treatments halt but do not cure the disease. This research suggests a need to also protect the neurons before the disease progresses to the late stage.

Commenting on the research, Dr Kennedy said, “By establishing a robust model for early and late stage diabetic retinopathy, we would hope to better understand the progression of the disease and pave the way for identifying new drug targets for its successful treatment”.

Explore further: Saudi Arabia: Deaths from MERS virus reach 348

Provided by University College Dublin

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Natural compound stops retinopathy

Jul 02, 2009

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a natural compound to stop one of the leading causes of blindness in the United States. The research appears online ...

Steroid injections may slow diabetes-related eye disease

Dec 15, 2009

Injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of diabetes that can cause vision loss and blindness, according to a report in the December issue of ...

Blocking protein may prevent blinding disease

Sep 16, 2009

Blocking a protein that battles infection may help thwart a common cause of vision loss in chronic diseases such as diabetes, Medical College of Georgia researchers say.

Recommended for you

At one month, US Ebola monitors finding no cases

2 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

3 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

Guinea, hit by Ebola, reports only one cholera case

3 hours ago

The health workers rode on canoes and rickety boats to deliver cholera vaccines to remote islands in Guinea. Months later, the country has recorded only one confirmed cholera case this year, down from thousands.

Sierra Leone official: Ebola worst could be over

3 hours ago

The Ebola outbreak in Sierra Leone, which has been surging in recent days, may have reached its peak and be on the verge of slowing down, Sierra Leone's information minister said Wednesday.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Apr 11, 2010
One might wonder exactly WHAT these researchers ARE studying when they MISS all the iron in the eye. It is well known iron in the eye destroys it. It is also well known there is MORE iron in the eye of a diabetic than is KNOWN to harm the eye but yet they FAIL to target this iron. How can someone KNOW something will destroy something and THEN fail to react TO that substance ? Stupidity is the only answer.
http://tinyurl.com/6x7y2

RESULTS: The level of vitreous iron
increased threefold in Eales' disease (1.85 +/- 0.36 pg/ml), 2.5-fold in
proliferative diabetic retinopathy (1.534 +/- 0.17 pg/ml) and 2.3-fold in eyes
with intraocular foreign body (1.341 +/- 0.25 pg/ml) when compared with macular
hole (0.588 +/- 0.16 pg/ml).

http://tinyurl.com/454x3

This suggests
that the least amount of ferrous ions necessary to cause liquefaction
of the rabbit vitreous is in the range of 16.8 to 39.2 micrograms of
elemental iron, a concentration of 0.3 to 0.7 mM in the vitreous.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.